Ignite Creation Date:
2025-12-24 @ 9:32 PM
Ignite Modification Date:
2026-01-01 @ 10:30 PM
Study NCT ID:
NCT00054132
Status:
COMPLETED
Last Update Posted:
2017-07-24
First Post:
2003-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2002-12
Start Date Type:
None
Primary Completion Date:
2015-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-04
Completion Date Type:
ACTUAL
First Submit Date:
2003-02-05
First Submit QC Date:
None
Study First Post Date:
2003-02-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-03-09
Results First Submit QC Date:
None
Results First Post Date:
2017-07-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-06-23
Last Update Post Date:
2017-07-24
Last Update Post Date Type:
ACTUAL